Scarica l'app Stockscreener
245.00
0.47%
1.2042
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$243.80
Aprire:
$247
Volume 24 ore:
3.33M
Relative Volume:
0.50
Capitalizzazione di mercato:
$432.76B
Reddito:
$62.82B
Utile/perdita netta:
$3.60B
Rapporto P/E:
120.85
EPS:
2.0274
Flusso di cassa netto:
$19.98B
1 W Prestazione:
-6.97%
1M Prestazione:
-6.17%
6M Prestazione:
+11.84%
1 anno Prestazione:
+23.37%
Intervallo 1D:
$243.76
$249.38
Intervallo di 1 settimana:
$242.38
$259.89
Portata 52W:
$190.75
$267.47
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
244.94 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,161.56 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.75 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
128.00 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.21 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis - TradingKey
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - TradingView
AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating - marketscreener.com
Should You Buy AbbVie Stock Hand Over Fist Before July 31? - The Motley Fool
AbbVie Seeks Block On Alkem Generic Constipation Drug - Law360
Former AbbVie, Amgen exec Severino takes the reins at Sarepta - FirstWord Pharma
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter - Fierce Pharma
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO - BioPharma Dive
AbbVie Researcher Dr. Jan Stoehr Outlines Use of Biomarkers to Target Parkinson’s Disease Progression - geneonline.com
Sarepta names former Abbvie president as CEO as Ingram retires - Reuters
Sarepta names former AbbVie R&D exec Michael Severino as next CEO - BioSpace
AbbVie stock hits all-time high of 261.71 USD - Investing.com
Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet - TIKR.com
How Abbvie Inc. (ABBV) Affects Rotational Strategy Timing - Stock Traders Daily
AbbVie Inc. (ABBV) Stock Analysis: A Healthcare Giant With A Promising 3.25% Upside - DirectorsTalk Interviews
ABBV|AbbVie Inc|Price:265.610|Chg%:+8.700 - TradingKey
AbbVie Inc Agencies, 2026 - OpenSecrets
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson? - The Motley Fool
AbbVie stock steadies as investors weigh Humira erosion against Skyrizi and Rinvoq growth - Ad-hoc-news.de
AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback - Yahoo Finance
AbbVie stock trades steadily as Humira erosion meets Skyrizi and Rinvoq growth - AD HOC NEWS
Should You Pay Attention To AbbVie Stock's Momentum? - Trefis
AbbVie stock may move 4.2% on July 31 earnings report By Investing.com - Investing.com Nigeria
AbbVie stock may move 4.2% on July 31 earnings report - Investing.com
AbbVie: A Dividend Fortress At An Appealing Price Tag - Seeking Alpha
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
AbbVie (ABBV) and Genmab's Epcoritamab Fails Key Trial Endpoint - GuruFocus
AbbVie, Genmab post trial setback for lymphoma drug (ABBV:NYSE) - Seeking Alpha
CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras SystemsNetflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS - Benzinga
AbbVie stock trades steadily as investors weigh Skyrizi and Rinvoq growth against Humira erosion - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Thermo Fisher (TMO) and AbbVie (ABBV) - The Globe and Mail
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint - Stock Titan
AbbVie: Bright Future, But Already Priced In (NYSE:ABBV) - Seeking Alpha
Donald TrumpABBVIE INC COM UNSOLICITED Trump Trade on Mar. 25, 2026 - Quiver Quantitative
AbbVie stock holds near record levels after second-quarter results - Ad-hoc-news.de
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Total equity of AbbVie, Inc. – BCS:ABBV0 - TradingView
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs - Bloomberg Law News
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2? - TradingView
Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating - marketscreener.com
Canaccord raises Abbvie stock price target to $282 on growth outlook - Investing.com
ABBV Maintains Buy Rating -- Price Target Raised to $282 by Cana - GuruFocus
ETFs Investing in AbbVie, Inc. Stocks - TradingView
How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin - Yahoo Finance
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow - The Motley Fool
EBIT per share of AbbVie, Inc. – BCS:ABBVCL1 - TradingView
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Abbvie Inc Azioni (ABBV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Purdue David Ryan | SVP, Controller |
Mar 04 '26 |
Sale |
233.56 |
5,230 |
1,221,519 |
2,654 |
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):